Calcipotriene plus betamethasone dipropionate gel: a new combination therapy for scalp psoriasis

References

• Christophers E. Psoriasis–epidemiology and clinical spectrum. Clin. Exp. Dermatol.26, 314–320 (2001).
   PubMed Web of Science ®Google Scholar
• Koo JY. Current consensus and update on psoriasis therapy: a perspective from the U.S. J. Dermatol.26, 23–33 (1999).
   PubMedGoogle Scholar
• Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom. Arch. Dermatol.141, 1537–1541 (2005).
   PubMed Web of Science ®Google Scholar
• Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life. Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol.137, 280–284 (2001).
   PubMed Web of Science ®Google Scholar
• Papp K, Berth-Jones J, Kragballe K, Wazel G, de la Brassinne M. Scalp psoriasis: a review of current topical treatment options. J. Eur. Acad. Dermatol. Venerol.21, 1151–1160 (2007)
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am. J. Clin. Dermatol.2, 159–165 (2001)
   PubMedGoogle Scholar
• Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin. Dermatol.26, 448–459 (2008).
   PubMed Web of Science ®Google Scholar
• Schoorl WJ, Baar HJ, van de Kerkhof PCM. The hair root patient in psoriasis of the scalp. Acta Derm. Venereol.72, 141–142 (1992).
   PubMed Web of Science ®Google Scholar
• Buckley C, Hoffmann V, Shapiro J, Saari S, Cambazard F, Milsgaard M. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a Phase II study. Dermatology217, 107–113 (2008).
   PubMed Web of Science ®Google Scholar
• Van de Kerkhof PCM, Salonen S-H; for the EUROPSO Patient Survey Study Group. Large-scale European survey of quality of life in patients with psoriasis: second phase results on quality of life and treatment reported by 7,525 members of European psoriasis patients associations. Published by the European Federation of Psoriasis Foundations (EUROPSO), Helsinki, Finland (2006).
   Google Scholar
• Lebwohl M, Ting PT, Koo JY. Psoriasis treatment: traditional therapy. Ann. Rheum. Dis.64(Suppl. 2), ii83–ii86 (2005).
   PubMed Web of Science ®Google Scholar
• Jarratt M, Breneman D, Gottlieb AB, Poulin Y, Liu Y, Foley V. Clobetasol piopionate shampoo 0.05%: a new option to treat patients with moderate-to-severe scalp psoriasis. J. Drugs Dermatol.3, 367–373 (2004).
   PubMedGoogle Scholar
• Zaghloul SS, Goodfield MJD. Objective assessment of compliance with psoriasis treatment. Arch. Dermatol.140, 408–414 (2004).
   PubMed Web of Science ®Google Scholar
• Fouéré S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J. Eur. Acad. Dermatol. Venereol.19(Suppl. 3), 2–6 (2005).
   PubMed Web of Science ®Google Scholar
• Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systemic review. Br. J. Dermatol.146, 351–364 (2002).
   PubMed Web of Science ®Google Scholar
• Olsen EA, Cram DL, Ellis CN et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J. Am. Acad. Dermatol.24, 443–447 (1991).
   PubMed Web of Science ®Google Scholar
• Franz TJ, Parsell DA, Halualani RM et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int. J. Dermatol.38, 628–632 (1999).
   PubMed Web of Science ®Google Scholar
• Melian EB, Spencer CM, Jarvis B. Clobetasol propionate foam, 0.05%. Am. J. Clin. Dermatol.2, 89–93 (2001).
   PubMedGoogle Scholar
• Høvding G. Treatment of psoriasis of the scalp with betamethasone 17, 21-dipropionate plus salicylic acid lotion (‘Diprosalic’). Pharmatherapeutica3, 61–66 (1981).
   PubMedGoogle Scholar
• Callis KP, Krueger GG. Topical agents in the treatment of moderate-to-severe psoriasis. In: Therapy of Moderate-to-Severe Psoriasis (2nd Edition). Weinstein GD, Gottlieb AB (Eds). Marcel Dekker, New York, USA 29–51 (2003).
   Google Scholar
• Thaci D, Daiber W, Boehncke WH et al. Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology203, 153–156 (2001).
   PubMed Web of Science ®Google Scholar
• Klaber MR, Hutchinson PE, Pedvis-Leftick A et al. Comparative effects of calcipotriol solution (50 µg/ml) and betamethasone 17-valerate solution (mg/ml) in the treatment of scalp psoriasis. Br. J. Dermatol.131, 678–683 (1994).
   PubMed Web of Science ®Google Scholar
• Reygagne P, Mrowietz U, Decroix J et al. Clobetasol propionate shampoo 0.05% and clacipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J. Dermatolog. Treat.16(1), 31–36 (2005).
   PubMed Web of Science ®Google Scholar
• Duweb GA, Abuzariba O, Rahim M et al. Scalp psoriasis: topical calcipotriol 50 micrograms/g/ml solution vs. betamethasone valerate 0.1% lotion. Int. J. Clin. Pharmacol. Res.20, 65–68 (2000).
   PubMedGoogle Scholar
• Barnes L, Altmeyer P, Fôrstrôm L, Stenström MH. Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur. J. Dermatol.10, 199–204 (2000).
   PubMed Web of Science ®Google Scholar
• Papp KA, Guenther L, Boyden B et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J. Am. Acad. Dermatol.48, 48–54 (2003).
   PubMed Web of Science ®Google Scholar
• Douglas WS, Poulin Y, Decroix J et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm. Venereol.82, 31–35 (2002).
   Web of Science ®Google Scholar
• Kaufmann R, Bibby AJ, Bissonnette R et al. A new calcipotriol/betamethasone dipropionate formujlation (Diavobet) is an effective once daily treatment for psoriasis vulgaris. Dermatology205, 389–393 (2002).
   PubMed Web of Science ®Google Scholar
• Guenther L, Cambazard F, van de Kerkhof PCM et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br. J. Dermatol.147, 316–323 (2002).
   PubMed Web of Science ®Google Scholar
• Kragballe K, Noerrelund KL, Lui H et al. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br. J. Dermatol.150, 1167–1173 (2004).
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomized, double-blind trial. Dermatology209(4), 308–313 (2004).
   PubMed Web of Science ®Google Scholar
• Downs AMR. Overnight application of Daivobet® ointment is effective in scalp psoriasis. Br. J. Dermatol.151(Suppl. 68), 52 (2004).
   Google Scholar
• Emerson RM, Howlett C. Successful treatment of scalp psoriasis with Dovobet® ointment. Br. J. Dermatol.151(Suppl. 68), 52–53 (2004).
   Google Scholar
• Bury Y, Ruf D, Hansen CM, Kissmeyer AM, Binderup L, Carlberg C. Molecular evaluation of vitamin D3 receptor agonists designed for topical treatment of skin diseases. J. Invest. Dermatol.116, 785–792 (2001).
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PCM. Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. Br. J. Dermatol.132, 675–682 (1995).
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PCM. In vivo effects of vitamin D3 analogues. J. Dermatol. Treat.9(Suppl. 3), S25–S29 (1998).
   Google Scholar
• Barna M, Bos JD, Kapsenberg ML, Snijdewint FG. Effect of calcitriol on the production of T-cell-derived cytokines in psoriasis. Br. J Dermatol.136, 536–541 (1997).
   PubMed Web of Science ®Google Scholar
• Vissers WH, Berends M, Muys L, van Erp PE, de Jong EM, van de Kerkhof PC. The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subset in chronic plaque psoriasis. Exp. Dermatol.13(2), 106–112 (2004).
   PubMed Web of Science ®Google Scholar
• El-Domyati M, Barakat M, Abdel-Razek R, El-Din Anbar T. Apoptosis, p53 and Bcl-2 expression in response to topical calcipotriol therapy for psoriasis. Int. J. Dermatol.46, 468–474 (2007).
   PubMed Web of Science ®Google Scholar
• Hamdi H, Godot V, Maillot MC et al. Induction of antigen-specific regulatory T lymphocytes by human dendritic cells expressing the glucocorticoid-induced leucine ziper. Blood110, 211–219 (2007).
   PubMed Web of Science ®Google Scholar
• Sugiyama H, Gyulai R, Toichi E et al. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol.174, 164–173 (2005).
   PubMed Web of Science ®Google Scholar
• Barrat FJ, Cua DJ, Boonstra A et al.In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med.195(5), 603–616 (2002).
   PubMed Web of Science ®Google Scholar
• Shupack JL, Jondreau L, Kenny C, Stiller MJ. Diflorasone diacetate ointment 0.05% versus betamethasone dipropionate ointment 0.05% in moderate–severe plaque-type psoriasis. Dermatology186, 129–132 (1993).
   PubMed Web of Science ®Google Scholar
• Beato M. Gene regulation by steroid hormones. Cell56, 335–344 (1989).
   PubMed Web of Science ®Google Scholar
• Meltzer EO. The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Allergy52, 33–40 (1997).
   PubMed Web of Science ®Google Scholar
• Gruyre PM, Girard MT, Morganelli PM, Manganiello PD. Glucocorticoid effects on the production and actions of immune cytokines. J. Steroid Biochem.30, 89–93 (1988).
   PubMedGoogle Scholar
• Stojadinovic O, Lee B, Vouthounis C et al. Novel genomic effects of glucocorticoids in epidermal keratinocytes: inhibition of apoptosis, interferon-gamma pathway, and wound healing along with promotion of terminal differentiation. J. Biol. Chem.282, 4021–4034 (2007).
   PubMed Web of Science ®Google Scholar
• Lamba S, Lebwohl M. Combination therapy with vitamin D analogs. Br. J. Dermatol.132, 675–682 (1995).
   PubMed Web of Science ®Google Scholar
• Patel B, Siskin S, Krazmien R, Lebwohl M. Compatibility of calcipotriene with other topical medications. J. Am. Acad. Dermatol.38(6 Pt 1), 1010–1011 (1998).
   PubMed Web of Science ®Google Scholar
• van Rossum MM, van Erp PEJ, van de Kerkhof PCM. Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study. Dermatology203, 148–152 (2001).
   PubMed Web of Science ®Google Scholar
• Simonsen L, Hoy G, Didriksen E, Persson J, Melchior N, Hansen J. Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle. Drug Dev. Ind. Pharm.30(10), 1095–1102 (2004).
   PubMed Web of Science ®Google Scholar
• Guenther L. Calcipotriene plus betamethasone: a new two-compound ointment for psoriasis. Expert Rev. Dermatol.1(6), 791–797 (2006).
   Google Scholar
• Xamiol® Product Monograph. Watermeadow Medical, Witney, UK (2008).
   Google Scholar
• Traulsen J. Bioavailability of betamethasone dipropionate when combined with calcipotriol. Int. J. Dermatol.43(8), 611–617 (2004).
   Web of Science ®Google Scholar
• Traulsen J, Hughes-Formella BJ. The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate oinment compared with betamethasone dipropionate ointment. Dermatology207, 166–172 (2003).
   PubMed Web of Science ®Google Scholar
• Jemec GBE, Ganslandt C, Ortonne J-P et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J. Am. Acad. Dermatol.59, 455–463 (2008).
   PubMed Web of Science ®Google Scholar
• van der Kerkhof PCM, Hoffmann V, Anstey A et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br. J. Dermatol.160, 170–176 (2009).
   PubMed Web of Science ®Google Scholar
• Kragballe K, Hoffmann V, Tan J, Ortonne JP. Calcipotriene plus betamethasone dipropionate gel compared to calcipotriene solution in patients with scalp psoriasis. J. Am. Acad. Dermatol.58(2, Suppl. 2), AB131 (2008).
   Web of Science ®Google Scholar
• Ortonne JP, Tan J, Nordin P, Ganslandt C. Quality of life of patients with scalp psoriasis treated with calcipotriene plus betamethasone dipropionate gel compared to calcipotriene solution. J. Am. Acad. Dermatol.58(2, Suppl 2), AB134 (2008)
   Google Scholar
• Luger TA, Cambazard F, Larsen FG et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology217, 321–328 (2008).
   PubMed Web of Science ®Google Scholar
• Tyring S, Bibby A. Calcipotriene/betamethasone dipropionate gel compared to gel vehicle in treating scalp psoriasis in Hispanic/Latino and black/African American patients. J. Am. Acad. Dermatol.58(2, Suppl. 2), AB125 (2008).
   Web of Science ®Google Scholar
• LEO Pharma. Taclonex Scalp® Topical Suspension, Xamiol®, Data on file.
   Google Scholar
• Poulin Y, Papp K, Bissonnette R et al. Twice weekly use of clobetasol propionate 0.05% shampoo is effective and safe for the long-term control of scalp psoriasis. Presented at: 17th Congress of the European Academy of Dermatology and Venereology. Paris, France, 17–21 September 2008.
   Google Scholar
• Lebwohl M, Yoles A, Lombardi K, Lou W. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J. Am. Acad. Dermatol.39, 447–450 (1998).
   PubMed Web of Science ®Google Scholar
• Holm EA, Jemec GBE. The therapeutic potential of calcipotriol in diseases other than psoriasis. Int. J. Dermatol.41, 38–43 (2002).
   PubMed Web of Science ®Google Scholar